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Introduction: Hyperglycemia, hypoglycemia and increased glucose variability are independently associated with
increased risk of death in critically ill adults. The relationship between time in targeted blood glucose range (TIR)
and mortality is not well described and may be a factor that has confounded the results of the major interventional
trials of intensive insulin therapy.
Methods: We conducted a retrospective analysis of prospectively collected data involving 3,297 patients with
intensive care unit (ICU) lengths of stay (LOS) of ≥1.0 day who were admitted between 1 January 2009 and 31
December 2013 to a single mixed medical-surgical ICU. We investigated the relationship between TIR 70 to
140 mg/dl with mortality and compared outcomes of non-diabetics (NON) and individuals with diabetes mellitus
(DM), including stratifying by TIR above (TIR-hi) and below (TIR-lo) the median value for the NON and DM groups.
Results: There were 85,799 blood glucose (BG) values for the NON group and 32,651 for the DM group, and we
found that 75.5% and 54.8%, respectively, were between 70 and 140 (P <0.0001). The median (interquartile range)
TIR (%) values for the NON and DM groups were 80.6% (61.4% to 94.0%) and 55.0% (35.5% to 71.1%), respectively
(P <0.0001). For the NON group, mortality was 8.47% and 15.71% for TIR-hi and TIR-lo, respectively (P <0.0001). For
the DM group, mortality was 16.09% and 14.44% for TIR-hi and TIR-lo, respectively (P = NS). We observed similar
relationships for the NON group when we stratified by ICU LOS or severity of illness, especially in the most severely
ill patients. There was a cumulative interaction of indices of hypoglycemia, hyperglycemia or glucose variability
with TIR. Multivariable analysis demonstrated, for the NON group, that TIR-hi was independently associated with
increased survival (P =0.0019). For the NON group, the observed-to-expected mortality ratios for TIR-hi and TIR-lo,
based on Acute Physiology and Chronic Health Evaluation IV methodology, were 0.53 and 0.78, respectively. In
contrast, among those in the DM group, there was no clear relationship between TIR 70 to 140 mg/dl and survival.
Conclusions: Independently of ICU LOS and severity of illness, TIR 70 to 140 mg/dl >80% is strongly associated
with survival in critically ill patients without diabetes. These findings have implications for the design of clinical
protocols for glycemic control in critically ill patients as well for the design of future interventional trials of intensive
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Time in targeted blood glucose range (TIR) may be a
suitable descriptor of the efficacy and safety of glycemic
control and could be considered as a marker of the severity
of dysglycemia and an index of the quality of care. Neither
the study that ushered in the era of “tight glycemic control”
nearly 14 years ago [1] nor the trial that dampened enthu-
siasm for intensive control of blood glucose (BG) values
8 years later [2] reported TIR.
The Glucontrol study was the only adult randomized
controlled trial (RCT) of intensive insulin therapy (IIT)
that reported TIR [3]. Only 27.8% of the values obtained in
patients in the experimental arm were within the targeted
BG range of 80 to 110 mg/dl. Subsequent analysis of these
data demonstrated that, for patients in either the intensively
treated or moderate arm, with a BG target of 140 to
180 mg/dl, TIR >50% was independently associated with an
increased rate of survival [4]. Chase and coinvestigators
have published a series of studies that assessed the
association of TIR (referred to as cumulative time in
band with organ failure mortality in a 784-patient,
before-and-after, single-center cohort evaluation of
their Specialized Relative Insulin Nutrition Tables
(SPRINT) protocol for IIT [5-7]. They concluded that
TIR ≥50% was independently associated with less organ
failure, as quantified by reduction in Sequential Organ
Failure Assessment (SOFA) score [6], and that TIR ≥70%
was independently associated with increased survival
compared with lower thresholds of TIR (≥30% and ≥ 50%)
[7]. Recently, Okabayashi and colleagues published a
single-center RCT demonstrating reduction in surgical
site infection with intensive vs. moderate BG targets,
notable for the very high TIR achieved in the two groups
with use of a closed-loop BG monitoring and insulin treat-
ment system [8]. In contrast, another recent multicenter
study in which computerized glucose control was used
failed to show any clinical benefit when TIR was low [9].
These data raise the possibility that low TIR may have
confounded the results of the major RCT of IIT and may
explain their uneven outcomes [1-3,10,11].
A robust literature has demonstrated that hyperglycemia,
hypoglycemia and increased glucose variability are inde-
pendently associated with mortality in diverse cohorts of
critically ill patients [12-22] and that diabetic status modu-
lates these relationships [23-25]. The outcome of patients
with diabetes mellitus (DM) may be less influenced
by dysglycemia than it is among patients without diabetes
(non-diabetic (NON)). Nevertheless, there is no firm
consensus about how to manage glycemia in the critically
ill, and some current guidelines have promoted BG targets
in the hyperglycemic range to mitigate the occurrence of
hypoglycemia [26-28].
We hypothesize that a high TIR is the key element of
glycemic control needed to effect optimal outcome andmay, in fact, blunt the deleterious impact of transient
excursions into the hypoglycemic and hyperglycemic
ranges. Accordingly, we evaluated the impact of a very
high TIR, such as >80%, a level not generally evaluated in
previous investigations, in a diverse population of critically
ill patients. In addition, we assessed the interrelationship
of TIR and diabetic status. To test these hypotheses, we
performed a retrospective analysis of a large cohort of




The study cohort included 3,247 patients admitted to
the Stamford Hospital ICU between 1 January 2009 and
31 December 2013 with an ICU LOS ≥1.0 day. During
this period, there were 4,976 admissions; patients who
required readmission or who had ICU LOS <1.0 day
were excluded from the analysis. The ICU treats adults
with a wide variety of medical and surgical conditions,
including those undergoing cardiovascular surgery. The
ICU has 16 beds and is staffed by full time respiratory
therapists. The nurse-to-patient ratio is 1:2 or 1:1,
depending on patient acuity. Stamford Hospital is a
major teaching hospital affiliate of Columbia University
College of Physicians and Surgeons located in Stamford,
CT, USA. All orders in the ICU are written by medical
or surgical residents supervised closely by medical and
surgical intensivists. We abstracted information from the
unit’s database. Gathered information included, in part,
demographics, comorbidities, severity of illness scores,
ICU LOS, ventilation metrics and hospital discharge
status. Of the 3,247 patients in the study cohort, 2,550
were non-diabetic (the NON group) and 747 were
diabetic (the DM group). Diabetic status was determined
prospectively by the Director of Critical Care (JSK) on
the basis of all clinical information available at the time
of ICU admission for the vast majority of patients; in a
small number of patients, diabetic status was determined
retrospectively by review of the electronic medical
records. The database does not include information about
whether DM was categorized as type 1 or type 2.
Glucose control
The BG target range during the study period was 90 to
120 mg/dl for all patients admitted to the ICU, a modest
upward revision of the target range shown to improve
mortality and morbidity of populations of critically ill
patients in previously published interventional trials
[5,6] (Additional file 1). This target was chosen explicitly
to maximize the percentage of values within a broader
70 to 140 mg/dl range, a range that the ICU nurses felt
that they could achieve. We chose this range because
(1) <70 mg/dl is a widely used definition of hypoglycemia
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hyperglycemia. Nurses performed BG monitoring using
ACCU-CHEK Inform II glucose meters (Roche Diagnostics,
Indianapolis, IN, USA) to test capillary, venous or arterial
blood. Monitoring guidelines precluded use of capillary
blood in the setting of shock or marked peripheral edema.
The measurement frequency was every 3 hours at a mini-
mum for all patients. Sustained hyperglycemia—two con-
secutive BG readings ≥180 mg/dl—triggered the institution
of continuous intravenous regular insulin infusion and
hourly BG measurement. The nurses treated lesser degrees
of hyperglycemia with subcutaneous insulin aspart at an
interval of every 3 hours. It is the standard of care in the
ICU to initiate nutritional support in the first 24 to 48 hours
of admission. Patients requiring more than 10 U/day of
insulin who were receiving a continuous source of calories
were typically administered insulin glargine to supply a
portion of their daily insulin requirement. The typical
starting dose of insulin glargine was one-third to one-half
of the previous 24-hour insulin requirement.
Metrics and statistical methods
We displayed continuous data as median (interquartile
range (IQR)) or mean (standard deviation) and made
comparisons between groups using the Mann–Whitney
rank-sum test or Student’s t-test, respectively, as appropri-
ate. We reported categorical data as percentages and made
comparisons between groups using the χ2 test.
We calculated TIR 70 to 140 mg/dl as the primary out-
come predictor. We calculated TIR using only recorded
values, without any data extrapolation. We stratified
outcomes using the median value of TIR, determined
separately for the NON and DM cohorts, by creating four
groups: TIR-hi and TIR-lo for the NON group and TIR-hi
and TIR-lo for the DM group. We analyzed their relation-
ship to mortality, defined as status at hospital, not ICU,
and discharge, and also stratified the analysis by incre-
ments of ICU LOS and the Acute Physiology Score (APS)
component of the Acute Physiology and Chronic Health
Evaluation (APACHE) IV severity scoring system [29]. We
constructed a multivariable model to investigate the
independent association of TIR with survival. We entered
parameters into the model that were statistically signifi-
cant in univariate analysis at a level of P <0.10. The final
model included age, APS, mechanical ventilation and ICU
LOS. Finally, we calculated the observed-to-expected
mortality ratio using APACHE IV predicted mortality.
We defined statistical significance as P <0.05. We
performed statistical analysis using MedCalc v13.3.3
software [30].
The Stamford Hospital Institutional Review Board
approved this investigation. Because of its retrospective
and observational nature, informed consent of the subjects
was not required.Results
Clinical characteristics and glycemic control metrics for
patients with or without diabetes
This investigation included 124,936 BG measurements,
of which 89,803 were obtained from patients without
diabetes (77.1% of the entire cohort) and 35,133 were
obtained from patients with diabetes (22.9% of the entire
cohort). The median (IQR) BG values for NON and DM
were 119 (104 to 138) and 132 (110 to 159), respectively
(P <0.0001).
Figure 1 displays the TIR data. The median TIR values
for the NON and DM groups were 80.6% and 55.0%,
respectively. Table 1 details important clinical characteris-
tics and glycemic control metrics of the study cohort,
stratified by diabetic status. Patients with diabetes were
older, had higher APS scores and APACHE IV predicted
mortality, and higher mortality than did patients without
diabetes. Patients with diabetes also had higher mean BG
values; greater glucose variability, as reflected by higher
coefficient of variation (CV); and higher rates of any
and severe hypoglycemia, defined as at least one BG
level <70 mg/dl or <40 mg/dl, respectively.Relationship of time in targeted blood glucose range to
mortality
Table 2 details important clinical characteristics and
glycemic control metrics of the study cohort for TIR-hi
and TIR-lo, stratified by diabetic status. In the NON
group, mortality was nearly twice as high for TIR-lo as for
TIR-hi, whereas the difference in mortality between TIR-hi
and TIR-lo was not significant in the DM group. We
constructed two sensitivity analyses. Figure 2 demonstrates
that, for the NON group, TIR-lo was strongly associated
with increased mortality compared with TIR-hi, especially
with longer ICU LOS. Figure 3 demonstrates that TIR-lo
was strongly associated with increased mortality compared
with TIR-hi, especially with higher APS scores. Among the
DM group, there was no significant relationship between
TIR and mortality.Interaction of domains of glycemic control
Table 3 illustrates the interaction of TIR and three
domains of glycemic control in the NON and DM
groups: hypoglycemia, defined as at least one BG
value <70 mg/dl; hyperglycemia, defined as at least one
BG value ≥180 mg/dl; and increased glucose variability,
defined as a CV ≥20%. These data demonstrate a strong
interaction between metrics of glycemic control in the
NON group, but not in the DM group. In the NON
group, even among those with high TIR, the presence
of concomitant hypoglycemia, hyperglycemia or increased
glucose variability was associated with increased risk
of death.
Table 1 Clinical characteristics and glycemic control overview for patients with or without diabetesa
NON DM P-value
Number 2,550 747
Age (yr) 67 (52 to 81) 70 (60 to 80) 0.0009
Median ICU LOS (IQR) 2.3 (1.5 to 5.0) 2.4 (1.6 to 5.0) 0.3004
Mean ICU LOS (SD) 4.5 (5.8) 4.6 (5.6) N/A
Mechanical ventilation (%) 48.20 51.94 0.0790
APS 51 (37 to 70) 60 (44 to 79) <0.0001
APACHE IV PM (%) 19.6 (23.5)b 25.4 (25.6)c <0.0001
Mortality (%) 12.12 15.26 0.0282
TIR 80.6 (61.4 to 94.0) 55.0 (35.3 to 71.1) <0.0001
Median number of BG tests (IQR) 17 (9 to 36) 22 (12 to 48) <0.0001
Mean number of tests (SD) 33.6 (45.8) 43.7 (59.1) N/A
BG tests per 24 hr 7.47 9.50
Mean BG 121.4 (111.5 to 132.6) 140.3 (127.6 to 154.9) <0.0001
CV (%) 17.6 (13.6 to 22.9) 27.3 (20.8 to 36.3) <0.0001
Hypo <70 (% of patients) 18.04 31.46 <0.0001
Hypo <40 (% of patients) 1.37 2.81 0.0118
aData are displayed as number, mean (SD), median (IQR) or percentage, as appropriate. Cardiovascular surgery patients did not have APACHE IV predicted
mortality calculated. APACHE, Acute Physiology and Chronic Health Evaluation; APS, Acute Physiology Score component of the APACHE IV predicted mortality
severity scoring system; BG, Blood glucose; CV, Coefficient of variation; DM, Diabetes mellitus group; Hypo, Hypoglycemia; ICU, Intensive care unit; IQR,
Interquartile range; LOS, Length of stay; N/A, Not appropriate; NON, Non-diabetic group; PM, Predicted mortality; SD, Standard deviation; TIR, Time in targeted
























Figure 1 Distribution of percentages time in targeted blood glucose range for patients without or with diabetes. DM, Diabetes mellitus group;
NON, Patients without diabetes mellitus; TIR, Time in targeted blood glucose range.
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Table 2 Comparison of time above and below targeted blood glucose range for patients with or without diabetes, as




Age (yr) 65 (48 to 80) 70 (56 to 82) <0.0001
Median ICU LOS (IQR) 2.2 (1.4 to 5.0) 2.4 (1.6 to 5.0) 0.0657
Mean ICU LOS (SD) 4.4 (5.6) 4.6 (5.9) N/A
Mechanical ventilation (%) 45.18 51.22 0.0026
APS 48 (34 to 67) 54 (40 to 74) <0.0001
APACHE IV PM (%) 16.6 (20.9) 22.9 (25.7) <0.0001
Mortality (%) 8.47 15.76 <0.0001
Glucose metrics
TIR (%) 94.0 (87.8 to 100.0) 61.4 (46.5 to 71.4) <0.0001
Median number of BG tests (IQR) 15 (9 to 35) 18 (10 to 39) 0.0001
Mean number of tests (SD) 30.7 (40.5) 36.6 (50.4) N/A
BG tests per 24 hr 7.0 8.0
Mean BG (SD) 113.4 (105.3 to 119.4) 131.9 (123.7 to 140.7) <0.0001
CV (%) 15.0 (11.6 to 19.2) 20.8 (16.3 to 25.8) <0.0001
Hypo <70 (% of patients) 16.63 19.45 0.0718
Hypo <40 (% of patients) 1.10 1.65 0.3066
DM group
Clinical parameters
Age (yr) 71 (61 to 80) 69 (59 to 80) 0.2418
Median ICU LOS (IQR) 2.7 (1.6 to 7.4) 2.1 (1.4 to 3.8) 0.0001
Mean ICU LOS (SD) 5.6 (6.5) 3.6 (4.4) N/A
Mechanical ventilation (%) 60.32 43.58 <0.0001
APS 63 (46 to 83)b 57 (44 to 75)c 0.0175
APACHE IV PM (%) 27.9 (25.4)d 22.7 (25.4)e 0.0071
Mortality (%) 16.09 14.44 0.5994
Glucose metrics
TIR (%) 71.1 (63.4 to 82.0) 35.4 (24.1 to 47.3) <0.0001
Median number of BG tests (IQR) 24 (13 to 62) 20 (12 to 36) 0.0023
Mean number of tests (SD) 52.0 (68.7) 35.4 (46.3) N/A
BG tests per 24 hr 9.3 9.8
Mean BG (SD) 129.6 (119.9 to 138.8) 151.7 (142.1 to 166.7) <0.0001
CV (%) 25.2 (19.3 to 33.8) 29.5 (22.2 to 37.7) <0.0001
Hypo <70 (% of patients) 38.07 24.87 0.0001
Hypo <40 (% of patients) 2.95 2.67 0.9919
aData are displayed as number, mean (SD), median (IQR) or percentage, as appropriate. Cardiovascular surgery patients did not have APACHE IV predicted
mortality calculated. APACHE, Acute Physiology and Chronic Health Evaluation; APS, Acute Physiology Score component of the APACHE IV predicted mortality
severity scoring system; BG, Blood glucose; CV, Coefficient of variation; DM, Diabetes mellitus group; Hypo, Hypoglycemia; ICU, Intensive care unit; IQR,
Interquartile range; LOS, Length of stay; N/A, Not appropriate; NON, Non-diabetic group; PM, Predicted mortality; SD, Standard deviation; TIR, Time in targeted
blood glucose range; TIR-hi, Time in targeted blood glucose range above median value for non-diabetic and diabetes mellitus groups; TIR-lo, Time in targeted
blood glucose range below median value for non-diabetic and diabetes mellitus groups. bn =1,227. cn =343. dn =1,099. en =340.
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Table 4 displays the results of multivariable analysis. Among
the NON group, TIR-lo was independently associated withincreased risk of death, with a 61% increase in the odds of
mortality. In contrast, there was no independent association























Figure 2 Relationship of time in range to mortality, stratified by intensive care unit length of stay, in the group of patients without diabetes. ICU
LOS, Intensive care unit length of stay; TIR-hi, Time in targeted blood glucose range above median value for non-diabetic and diabetes mellitus





























Figure 3 Relationship of time in range to mortality, stratified by Acute Physiology Score, in the group of patients without diabetes. APS, Acute
Physiology Score component of the Acute Physiology and Chronic Health Evaluation IV severity scoring system; TIR-hi, Time in targeted blood
glucose range above median value for non-diabetic and diabetes mellitus groups; TIR-lo, Time in targeted blood glucose range below median
value for non-diabetic and diabetes mellitus groups.
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Table 3 Interaction of domains of glycemic control with
time in targeted blood glucose rangea
Number Mortality (%) P-value
NON group
TIR-hi
Min BG ≥70 mg/dl 1,063 6.49 <0.0001
Min BG <70 mg/dl 212 18.40
CV <20% 1,007 6.85 <0.0001
CV ≥20% 268 15.30
Max BG <180 mg/dl 1,041 6.82 <0.0001
Max BG ≥180 mg/dl 234 15.81
TIR-lo
Min BG ≥70 mg/dl 1,027 11.39 <0.0001
Min BG <70 mg/dl 248 33.87
CV <20% 585 9.23 <0.0001
CV ≥20% 690 21.30
Max BG <180 mg/dl 474 10.76 0.0002
Max BG ≥180 mg/dl 801 18.73
DM group
TIR-hi
Min BG ≥70 mg/dl 231 10.82 0.0007
Min BG <70 mg/dl 142 24.65
CV <20% 102 10.78 0.1206
CV ≥20% 271 18.08
Max BG <180 mg/dl 94 14.89 0.8392
Max BG ≥180 mg/dl 279 16.49
TIR-lo
Min BG ≥70 mg/dl 281 14.23 0.9802
Min BG <70 mg/dl 93 15.05
CV <20% 61 14.75 0.9014
CV ≥20% 313 14.38
Max BG <180 mg/dl 28 14.29 0.7977
Max BG ≥180 mg/dl 346 14.45
aBG, Blood glucose; CV, Coefficient of variation; DM, Diabetes mellitus group;
Max, Maximum; Min, Minimum; NON, Non-diabetic group; TIR, Time in
targeted blood glucose range 70 to 140 mg/dl; TIR-hi, Time in targeted
blood glucose range above median value for non-diabetic and diabetes
mellitus groups; TIR-lo, Time in targeted blood glucose range below median
value for non-diabetic and diabetes mellitus groups.
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the substantially lower observed-to-expected mortality ratio
in the NON group, using APACHE IV methodology, of
TIR-hi compared with TIR-lo.
Discussion
In this retrospective analysis of a large, heterogeneous
cohort of critically ill patients, we investigated the
relationship between TIR 70 to 140 mg/dl and mortality.
The salient finding of the study is that TIR was stronglyassociated with survival among patients without diabetes,
with a 61% increase in the odds of death when we
compared patients below and above the median value
for TIR. The association between TIR and mortality
was independent of severity of illness, with the greatest
difference demonstrated in the subpopulation with the
highest severity of illness. In addition, the association
between TIR and mortality was independent of ICU LOS.
Notably, TIR-hi was strongly associated with survival
among patients with ICU LOS of 1 to 3 days; earlier data
derived from interventional trials suggested no benefit of
glycemic control in a short-stay cohort [1,10].
In contrast, among patients with DM in the present
study, there was no consistent relationship between TIR
and mortality. Glycemic control differed substantially
among patients with vs. without DM. Although BG targets
and glycemic control guidelines in the ICU did not
differ based on diabetic status, patients with DM had
higher mean BG, higher glucose variability, higher rates of
hypoglycemia and a much lower TIR than did those
without DM. These divergent findings are consistent with
recent literature describing differences between patients
with vs. without diabetes regarding the relationships of
hyperglycemia, hypoglycemia and glucose variability to
mortality [23-25].
These data expand on the limited literature that has
explored the relationship between TIR and mortality in
critically ill patients. Chase and colleagues evaluated the
clinical impact of a computerized glycemic control
protocol requiring BG measurement every 1 to 2 hours
that controlled insulin infusion and nutrition input
concomitantly [5]. Using a before-and-after experimental
design, they demonstrated reduced mortality in the
interventional group among those staying in the ICU for
3 to 5 days [6]. Subsequent analysis included the entire
cohort of 784 patients to investigate the relationship
between TIR 72 to 126 mg/dl and clinical endpoints [6,7].
TIR ≥50% was independently associated with reduced
organ failure, as shown by fewer patients with SOFA
scores ≤5 after day 5 in the ICU [6]. In addition,
TIR ≥70% was independently associated with increased
odds of survival compared with TIR ≥50% or TIR ≥30%
[7]. These investigations did not stratify patients by
diabetic status (17% of the entire cohort).
Our findings shed light on the varied results of the
interventional trials of IIT. Intensive monitoring of BG
levels and treatment of hyperglycemia became a worldwide
standard of care following publication of a single-center
study conducted in a population of mechanically ventilated
surgical patients that demonstrated marked reductions in
mortality and morbidity in patients treated with intra-
venous insulin and a BG target of 80 to 110 mg/dl [1].
Subsequent interventional trials failed to reproduce these
impressive findings [2,3,10,11]. Only one of these studies
Table 4 Multivariable analysis: association with mortalitya
Variable Coefficient Standard error OR (95% CI) P value
NON group
Age 0.0213 0.0049 1.02 (1.02 to 1.03) <0.0001
APS 0.0499 0.0031 1.05 (1.04 to 1.06) <0.0001
Mechanical ventilation 0.7025 0.1794 2.02 (1.42 to 2.87) 0.0001
TIR-lo 0.4744 0.1531 1.61 (1.19 to 2.17) 0.0019
DM group
Age 0.0364 0.0102 1.04 (1.02 to 1.06) 0.0004
APS 0.0532 0.0054 1.05 (1.04 to 1.07) <0.0001
Mechanical ventilation 0.6886 0.3177 1.99 (1.07 to 3.71) 0.0302
TIR-lo 0.0780 0.2610 1.08 (0.65 to 1.80) 0.7649
aAge, OR per 1 year. APS, OR per 1 point. APS, Acute Physiology Score component of the Acute Physiology and Chronic Health Evaluation IV predicted mortality
severity scoring system; CI, Confidence interval; DM, Diabetes mellitus group; NON, Non-diabetic group; OR, Odds ratio; TIR-hi, Time in targeted blood glucose
range above median value for non-diabetic and diabetes mellitus groups; TIR-lo, Time in targeted blood glucose range below median value for non-diabetic and
diabetes mellitus groups.
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Monitoring Board for that study forced the premature
termination of the study because of the low TIR. Estimates
of TIR in the intensive insulin arm for the major interven-
tional trials, inferred using the reported morning BG values
and the standard normal distribution table, range from
31% [2] to 53% [1]. However, the comparison of TIR of
these studies is confounded by the differences in the
number of BG values used and in BG monitoring, including
the use of arterial blood and blood gas analyzers [1] or




























Figure 4 Observed-to-expected mortality ratio for of time above and belo
diabetes. TIR-hi, Time in targeted blood glucose range above median value
blood glucose range below median value for non-diabetic and diabetes manalyzers and bedside glucometers [2,3,10,11]. None of
these studies reported BG monitoring frequency.
In contrast to these findings, Okabayashi and coworkers
performed a single-center RCT in 447 patients undergoing
hepatobiliary or pancreatic surgery to compare infection
rates in those with BG targets of 80 to 110 mg/dl and 140
to 180 mg/dl, the same targets used in the Normoglycemia
in Intensive Care Evaluation and Surviving Using Glucose
Algorithm Regulation trial (referred to as NICE-SUGAR)
[8]. They used a computerized, closed-loop BG moni-
toring and insulin delivery system to achieve veryTIR lo
w targeted blood glucose range in the group of patients without
for non-diabetic and diabetes mellitus groups; TIR-lo, Time in targeted
ellitus groups.
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respectively—without significant differences between
patients with and without DM. Notably, surgical site
infection, the primary outcome, occurred in 9.8% of
patients treated with the intermediate BG target and
4.1% of those treated with the “tight” BG target (P =0.028).
This intriguing investigation is, in fact, hypothesis-
generating. Although a high rate of hypoglycemia in
the intensively treated patients of the major interventional
trials of IIT has been independently associated with
increased risk of death in all of the studies [1-3,10,11,14,15],
and though elevated glucose variability has been inde-
pendently associated with increased risk of death in
two of them [14], it is quite possible that the low
TIR contributed to the finding of lack of benefit of
the intervention. This conclusion is supported by a
recently published post hoc analysis of the multicenter
Glucocontrol trial of IIT [4]. The Glucocontrol trial
was terminated prematurely because of the low rate
of achieving the targeted BG for the patients in the
interventional arm. The new analysis concludes that,
though there was no difference in the development of
organ failure based on intention to treat to different
glycemic targets (BG 80–110 mg/dl in the intensive
arm and 140 to 180 mg/dl in the conventional arm),
achieving the BG range of 72 to 136 mg/dl was inde-
pendently associated with increased survival for patients
in either arm of the trial.
The present study has several strengths. The large
dataset is robust, containing a comprehensive set of clinical
parameters. The patients were treated consistently over the
period of time they were included in the study, with a high
frequency of BG measurements exceeding that commonly
seen in clinical practice [22]. The analysis includes an
explicit detailing of the relationship of TIR to survival, as
well as its interaction with the other domains of glycemic
control: hyperglycemia, hypoglycemia and glucose variabil-
ity. Finally, the investigation stratifies patients by diabetic
status, a factor increasingly recognized in the literature
regarding glycemic control in critically ill patients [23-25].
There are several limitations of the present study.
First, the major limitation is its observational nature.
Consequently, its conclusions must be considered
hypothesis-generating rather than as proof of causality.
Nevertheless, it is unlikely that a randomized trial will ever
be conducted that stratifies patients into a TIR-lo cohort.
Second, we conducted a single-center study, raising
questions about its generalizability. However, the ICU
treats a heterogeneous population of critically ill adults
admitted with a wide array of medical and surgical diagno-
ses. Third, there is significant mathematical coupling
between TIR and the other established domains of
glycemic control hyperglycemia, hypoglycemia and glucose
variability. A patient with low TIR is certainly more likelyto have higher rates of dysglycemia reflected by the other
three glucose metrics. Nevertheless, the data in Table 3
demonstrate, especially for non-diabetics, that concomitant
hypoglycemia, hyperglycemia or increased glucose
variability, regardless of TIR, was associated with increased
risk of death. Fourth, we do not have hemoglobin A1c
values for the patients. Some patients characterized as
non-diabetic may, in fact, have more properly been charac-
terized as previously undiagnosed diabetics. Fifth, we do
not provide data about nutritional support or insulin
therapy; subsequent work may help delineate the interplay
between these factors and glycemic control. Finally, the
ICU staff employed glucometers for BG analysis, using
capillary blood in the majority of tests and venous or
arterial blood in the remaining. Although this method
of analysis has been associated with analytic inaccuracies
[31-33], it remains the standard of care in many ICUs,
especially in the United States.
These findings have implications relating to current
clinical practice, to the assessment of quality of care and
for the design of future interventional trials using new
methods to improve glucose control. We have shown
that TIR 70 to 140 mg/dl is independently associated
with survival in a heterogeneous cohort of critically ill
patients without diabetes. Nevertheless, one of the lessons
of the interventional trials of glycemic control is that high
TIR is an elusive target that is very difficult to achieve.
Computer-guided insulin administration algorithms may
be one way to increase TIR and consequently improve
glycemic control. The Leuven investigators have demon-
strated that use of a computer-guided algorithm increased
TIR from 60.1% to 68.8% compared with the BG control
efforts of their well-trained nurses [34]. Similarly, Juneja
and coworkers used a software program to guide insulin
therapy targeting 80 to 110 mg/dl in 4,488 ICU patients,
achieving TIR of 73.4% [35]. Nevertheless, 4.2% of patients
sustained at least one episode of severe hypoglycemia
(BG <40 mg/day). The investigators concluded that meas-
urement delay (mean of only 12 minutes, with a proto-
col requiring hourly monitoring) was contributory in
two-thirds of these episodes.
Importantly, even hourly BG monitoring is associated
with a high likelihood of missed excursions into the
hyperglycemic and hypoglycemic ranges. This has been
clearly demonstrated in studies in which researchers
investigated continuous or near-continuous BG monitors
[36,37], suggesting that increased BG monitoring fre-
quency may provide the best path to achieving high TIR.
Indeed, in a recently published Monte Carlo simula-
tion of the impact of monitoring frequency on the occur-
rence of hyperglycemia and hypoglycemia, investigators
determined that rates of dysglycemia decreased substan-
tially when monitoring frequency was increased from
every 2 hours to every 1 hour, with further modest
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to every 15 minutes [38].
These data suggest the possibility that TIR may be a
useful quality-of-care metric for assessing glucose control
practice in an ICU in view of its ease of measurement and
strong association with risk of death. Finally, we believe
that the findings of the present study have important
implications for the design of future interventional trials
of IIT in critically ill patients. First, our data confirm that
the optimal target for BG control in critically ill patients
with diabetes has not yet been established, a finding that is
consistent with recent observational literature [23-25].
Clinical equipoise may now exist for the implementation
of an interventional trial incorporating multiple BG
targets, based on patient characteristics, including diabetic
status and, for patients with diabetes, preexisting glycemic
control [39,40] Most importantly, achieving a high TIR,
such as >80%, must be considered as integral to the
success of the trial. Notably, the number of patients
needed for a trial will likely be much lower than the
numbers participating in the previously published
interventional trials if TIR is very high, as demonstrated
by a recently published study using a closed-loop insulin
delivery system that in which researchers found a reduc-
tion in surgical site infection when they compared inten-
sive and moderate BG targets, with just over 200 patients
in each arm of the study [8]. These findings cannot be
achieved with the monitoring technologies and the
monitoring frequencies used in the published interven-
tional trials of IIT [41]. In future trials, investigators must
consider use of the new emerging technologies that allow
continuous or near-continuous BG monitoring.
Conclusions
In this retrospective evaluation of a heterogeneous cohort
of critically ill patients, we demonstrate that TIR 70 to
140 mg/dl was independently associated with survival
among patients without diabetes. There was a 61% in-
crease in the odds of death among non-diabetics when we
compared patients below and above the median value for
TIR. This association was seen consistently, regardless of
ICU LOS, including those with short ICU LOS, and was
strongest for those patients with the highest severity
of illness. The relationship between TIR and mortality
among patients with diabetes was less clear, and glucose
control among this group of patients was challenging,
with higher mean BG, higher glucose variability and
higher rates of hypoglycemia compared with results
in patients without diabetes, even though the number
of BG measurements was higher among patients with
diabetes than in those without diabetes. These findings
have important implications for current clinical practice
as well as for the design of future interventional trials of
IIT in critically ill patients.Key messages
 TIR 70 to 140 mg/dl is independently associated
with survival in critically ill patients without
diabetes, with a nearly twofold increase in mortality
between patients below and above the median value
for TIR, 80.6%.
 This relationship is independent of ICU LOS and
severity of illness.
 The metrics of glycemic control in individuals
without diabetes, including TIR, hypoglycemia,
hyperglycemia and glucose variability, exceed those
seen in patients with diabetes.
 These findings have important implications for current
clinical practice as well as for the design of future
interventional trials of IIT in critically ill patients.
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